Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Pharmacological therapies for muscular dystrophies.

Abdel-Hamid H, Clemens PR.

Curr Opin Neurol. 2012 Oct;25(5):604-8. doi: 10.1097/WCO.0b013e328357f44c. Review.

PMID:
22941265
2.

The muscular dystrophies.

Flanigan KM.

Semin Neurol. 2012 Jul;32(3):255-63. doi: 10.1055/s-0032-1329199. Epub 2012 Nov 1. Review.

PMID:
23117950
3.

Muscular dystrophy: new challenges and review of the current clinical trials.

Mercuri E, Muntoni F.

Curr Opin Pediatr. 2013 Dec;25(6):701-7. doi: 10.1097/MOP.0b013e328365ace5. Review.

PMID:
24240289
4.

Treatment of muscular dystrophies.

Kingston WJ, Moxley RT.

Gen Pharmacol. 1989;20(3):263-8. Review.

PMID:
2663627
5.

Therapeutic advances in muscular dystrophy.

Leung DG, Wagner KR.

Ann Neurol. 2013 Sep;74(3):404-11. doi: 10.1002/ana.23989. Review.

6.

New therapies in muscular dystrophies.

Angelini C, Bonifati DM.

Neurol Sci. 2000;21(5 Suppl):S919-24. Review.

PMID:
11382190
7.

Oral health considerations in muscular dystrophies.

Balasubramaniam R, Sollecito TP, Stoopler ET.

Spec Care Dentist. 2008 Nov-Dec;28(6):243-53. doi: 10.1111/j.1754-4505.2008.00047.x. Review.

PMID:
19068065
8.
9.

Adjuvant therapy for atrial fibrillation.

Mohammed KS, Kowey PR, Musco S.

Future Cardiol. 2010 Jan;6(1):67-81. doi: 10.2217/fca.09.57. Review.

PMID:
20014988
10.

[Pharmacological treatments for Duchenne and Becker dystrophies].

Voisin V, de la Porte S.

J Soc Biol. 2005;199(1):17-28. Review. French.

PMID:
16114260
11.

Hereditary muscular dystrophies and the heart.

Hermans MC, Pinto YM, Merkies IS, de Die-Smulders CE, Crijns HJ, Faber CG.

Neuromuscul Disord. 2010 Aug;20(8):479-92. doi: 10.1016/j.nmd.2010.04.008. Review.

PMID:
20627570
12.

Cardiac management in neuromuscular diseases.

Allen HD, Thrush PT, Hoffman TM, Flanigan KM, Mendell JR.

Phys Med Rehabil Clin N Am. 2012 Nov;23(4):855-68. doi: 10.1016/j.pmr.2012.08.001. Review.

PMID:
23137741
13.

Etiology and pathogenesis of the muscular dystrophies.

Van den Bergh PY, Tomé FM, Fardeau M.

Acta Neurol Belg. 1995;95(3):123-41. Review.

PMID:
7484050
14.

[The genetic basis of muscle disease].

Bindoff L, Gilhus NE.

Tidsskr Nor Laegeforen. 2003 Sep 25;123(18):2588-92. Review. Norwegian.

PMID:
14714051
15.

Pharmacological strategies for muscular dystrophy.

Khurana TS, Davies KE.

Nat Rev Drug Discov. 2003 May;2(5):379-90. Review.

PMID:
12750741
16.

Genetic modifiers of Duchenne and facioscapulohumeral muscular dystrophies.

Hightower RM, Alexander MS.

Muscle Nerve. 2018 Jan;57(1):6-15. doi: 10.1002/mus.25953. Epub 2017 Sep 22. Review.

17.

Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies.

Chakkalakal JV, Thompson J, Parks RJ, Jasmin BJ.

FASEB J. 2005 Jun;19(8):880-91. Review.

PMID:
15923398
18.

Outlook for therapy in the muscular dystrophies.

Tawil R.

Semin Neurol. 1999;19(1):81-6. Review.

PMID:
10711991
19.

[Therapeutic strategy for muscular dystrophies].

Shin JH, Takeda S.

Brain Nerve. 2007 Apr;59(4):415-24. Review. Japanese.

PMID:
17447528
20.

The muscular dystrophies.

Wicklund MP.

Continuum (Minneap Minn). 2013 Dec;19(6 Muscle Disease):1535-70. doi: 10.1212/01.CON.0000440659.41675.8b. Review. Erratum in: Continuum (Minneap Minn). 2014 Jun;20(3 Neurology of Systemic Disease):520.

PMID:
24305447

Supplemental Content

Support Center